An investigation of effect and safety of Apatinib in the treatment of advanced NSCLC

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17013445

Enrollment

Unknown

Registered

2017-11-19

Start date

2017-12-01

Completion date

Unknown

Last updated

2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

Case series:Apatinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years men and women; 2. NSCLC patients who failed or relapsed after second-line treatment; 3. Patients who can benefit from Apatinib; 4. With written informed consent signed voluntarily by patients themselves and with good compliance and agree to accept follow-up of disease progression and adverse events.

Exclusion criteria

Exclusion criteria: 1. Allergic patients who Has been confirmed of apatinib or its accessories; 2. Pregnant or lactated women; 3. Other conditions regimented at investigators' discretion.

Design outcomes

Primary

Measure	Time frame
Safety;	—

Secondary

Measure	Time frame
OS;PFS;ORR;DCR;QoL;	—

Countries

China

Contacts

Public ContactXiaohua HU

Department of oncology, the First Affiliated Hospital of Guangxi Medical University

285590134@qq.com+86 13507719316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026